Atlas Venture Life Science Advisors, LLC — 13F Holdings & Portfolio

CIK 1917529 · latest 13F-HR filed 2026-11-10

Atlas Venture Life Science Advisors, LLC manages $631.2M in 13F-reported U.S. long-equity assets across 9 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are KYMR (50.43%), IRON (14.35%), OBX (9.80%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 2 new positions and exited 0; 0 existing positions rose in reported value and 6 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$631.2M

Long-equity book

Holdings
9

Distinct positions

Period
2026-09-30

Filed 2026-11-10

Q/Q Activity
+2 / −0 / ↑0 / ↓6

vs 2026-06-30

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q3 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q2 26 → Q3 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

5 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 100%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 31, 2026.

Address
300 TECHNOLOGY SQUARE
8TH FLOOR
CAMBRIDGE, MA 02139
Phone
(857) 201-2700
Name Title / Status Ownership Type
BOOTH, BRUCE, LEE ControlMEMBER
since Nov 2014
25–50%Individual
Bitterman, Kevin ControlMEMBER
since Jun 2017
25–50%Individual
Michael, Gladstone ControlMEMBER
since Jul 2020
25–50%Individual
RHODES, JASON, PAUL ControlMEMBER
since Nov 2014
25–50%Individual
CHOHAN, OMMERCFO
since Apr 2015
Less than 5%Individual
Ownership & leadership changes · 4 filings with changes since Feb 19, 2015

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 31, 2026 filing
  • No longer listedFORMELA, JEAN-FRANCOIS, BERNARD · MEMBER · 10–25% · control person · listed since Nov 2014
  • No longer listedGRAYZEL, DAVID · MEMBER · 10–25% · control person · listed since Nov 2014
  • ChangedBOOTH, BRUCE, LEE · ownership 10–25% → 25–50%
  • ChangedBitterman, Kevin · ownership 10–25% → 25–50%
  • ChangedMichael, Gladstone · ownership 10–25% → 25–50%
  • ChangedRHODES, JASON, PAUL · ownership 10–25% → 25–50%
Jun 8, 2021 filing
  • AddedMichael, Gladstone · MEMBER · 10–25% · control person
Mar 30, 2018 filing
  • No longer listedBARRETT, PETER · MEMBER · 10–25% · control person · listed since Nov 2014
  • AddedBitterman, Kevin · MEMBER · 10–25% · control person
Jan 11, 2016 filing
  • AddedCHOHAN, OMMER · CFO · Less than 5%
Feb 19, 2015 filing (earliest on record)
  • ListedBARRETT, PETER · MEMBER · 10–25% · control person
  • ListedBOOTH, BRUCE, LEE · MEMBER · 10–25% · control person
  • ListedFORMELA, JEAN-FRANCOIS, BERNARD · MEMBER · 10–25% · control person
  • ListedGRAYZEL, DAVID · MEMBER · 10–25% · control person
  • ListedRHODES, JASON, PAUL · MEMBER · 10–25% · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Top Adds (vs prior quarter)

  • No increased positions.
Show all 0 →

Top Trims

Show all 6 →

Exited Positions

  • No exits this quarter.
Show all 0 →

Atlas Venture Life Science Advisors, LLC Holdings (2026-09-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 Kymera Therapeutics, Inc. KYMR 501575104 $318.3M 50.43% 2,847,541 SH
2 Disc Medicine, Inc. IRON 254604101 $90.6M 14.35% 1,384,025 SH
3 Obsidian Therapeutics, Inc. OBX 67448A106 $61.8M 9.80% 4,503,149 SH
4 Kailera Therapeutics, Inc. KLRA 482931102 $59.1M 9.36% 5,171,282 SH
5 Dyne Therapeutics, Inc. DYN 26818M108 $55.4M 8.78% 3,440,720 SH
6 Q32 Bio, Inc. QTTB 746964105 $22.5M 3.56% 2,717,106 SH
7 Sionna Therapeutics, Inc. SION 829401108 $15.8M 2.50% 2,995,602 SH
8 Korro Bio, Inc. KRRO 500946108 $7.7M 1.21% 773,260 SH
9 Odyssey Therapeutics, Inc. ODTX 67613T104 $59.8K 0.01% 2,692 SH
Filing History
Period Filed AUM Holdings Accession
2026-09-30 2026-11-10 $631.2M 9 0001104659-26-125242
2026-06-30 2026-08-13 $881.3M 7 0001104659-26-095933
2026-03-31 2026-05-14 $790.0M 6 0001104659-26-061232
2025-12-31 2026-02-13 $865.2M 8 0001104659-26-014463
2025-09-30 2025-11-13 $752.6M 9 0001104659-25-111321
Filer Information
Address
300 TECHNOLOGY SQUARE, 8TH FLOOR
CAMBRIDGE, MA 02139
Phone
(857) 201-2700
Filing Manager
Atlas Venture Life Science Advisors, LLC
CAMBRIDGE, MA
Signatory
Ommer Chohan
CFO